Nanobiotix
Nanobiotix is a pioneering biotechnology company focused on the discovery, development, manufacture, and commercialization of physics-based nanotherapeutics. Their mission is to create innovative treatments that improve health outcomes for millions of people with cancer and other challenging diseases, utilizing nanotechnologies such as NBTXR3 and Curadigm platforms. The company is committed to expanding the possibilities of nanomedicine through physics-based approaches that transcend biological limitations, aiming for broad applicability across various diseases and patient populations.
Industries
Nr. of Employees
medium (51-250)
Nanobiotix
60 rue de Wattignies, 75012 Paris France
Patents
Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer
US-11819548-B2
View DetailsPharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof
US-11471410-B2
View DetailsNanoparticles for use in enhancing brain performances or in treating stress
US-11471482-B2
View Details
Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer
US-11819548-B2
View DetailsPharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof
US-11471410-B2
View DetailsNanoparticles for use in enhancing brain performances or in treating stress
US-11471482-B2
View DetailsProducts
Radiotherapy-activated nanoparticle therapeutic (radioenhancer)
Intratumoral nanoparticle formulation composed of biocompatible hafnium oxide designed to enhance radiotherapy energy deposition in injected tumor tissue and to be administered in conjunction with external radiotherapy.
Nanoprimer platform for transient pharmacokinetic modulation
Lipid nanoparticle-based priming agent designed to transiently occupy hepatic clearance pathways to increase circulating exposure and target-tissue accumulation of intravenously administered therapeutics.
Radiotherapy-activated nanoparticle therapeutic (radioenhancer)
Intratumoral nanoparticle formulation composed of biocompatible hafnium oxide designed to enhance radiotherapy energy deposition in injected tumor tissue and to be administered in conjunction with external radiotherapy.
Nanoprimer platform for transient pharmacokinetic modulation
Lipid nanoparticle-based priming agent designed to transiently occupy hepatic clearance pathways to increase circulating exposure and target-tissue accumulation of intravenously administered therapeutics.
Services
Structuring and executing global licensing and co-development agreements with pharmaceutical partners to advance clinical development and commercialization of nanoparticle therapeutics.
Design and operational support for oncology clinical trials across multiple phases and indications, including collaboration with academic centers and multi-site trial management.
Provision of educational materials, trial listings and patient-facing resources to inform patients and healthcare providers about ongoing studies.
Development of clinical procedural guidelines and training materials for intratumoral and intranodal nanoparticle injection to support standardized administration in trials and clinical practice.
Structuring and executing global licensing and co-development agreements with pharmaceutical partners to advance clinical development and commercialization of nanoparticle therapeutics.
Design and operational support for oncology clinical trials across multiple phases and indications, including collaboration with academic centers and multi-site trial management.
Provision of educational materials, trial listings and patient-facing resources to inform patients and healthcare providers about ongoing studies.
Development of clinical procedural guidelines and training materials for intratumoral and intranodal nanoparticle injection to support standardized administration in trials and clinical practice.
Expertise Areas
- Physics-based nanomedicine development
- Radiotherapy dose-enhancement strategies
- Nanoparticle formulation and biomaterials (hafnium oxide, lipid nanoparticles)
- Nanoprimer approaches for pharmacokinetic modulation
Key Technologies
- Radiotherapy-activated nanoparticles
- Hafnium oxide nanoparticle formulations
- Lipid nanoparticle priming agents to modulate hepatic clearance
- Intratumoral and intranodal injection delivery techniques
News & Updates
Recent Scientific Publications on Nanobiotix Technologies
Nanobiotix's scientific publications highlight advancements in nanotherapy, immuno-oncology, and clinical trial results, demonstrating the company's ongoing research efforts and technological innovations.
CE Marking for NBTXR3 (Hensify®) in Europe
Obtained CE marking for the treatment of locally advanced soft tissue sarcoma in 27 European countries.
Multiple Clinical Trials Ongoing for NBTXR3
14 clinical trials across various indications including head and neck, lung, and pancreatic cancers.
Recent Scientific Publications on Nanobiotix Technologies
Nanobiotix's scientific publications highlight advancements in nanotherapy, immuno-oncology, and clinical trial results, demonstrating the company's ongoing research efforts and technological innovations.
CE Marking for NBTXR3 (Hensify®) in Europe
Obtained CE marking for the treatment of locally advanced soft tissue sarcoma in 27 European countries.
Multiple Clinical Trials Ongoing for NBTXR3
14 clinical trials across various indications including head and neck, lung, and pancreatic cancers.